What is it about?
This study examines how different COVID-19 vaccination strategies impacted infections and deaths in Thailand, a middle-income country that faced vaccine shortages early in the pandemic. The researchers used mathematical modeling to compare various approaches, including mixing different vaccine types and prioritizing certain age groups. They found that using all available vaccines in parallel or mixing vaccine types was more effective than relying on just one vaccine. Faster vaccine rollout speeds were crucial in reducing COVID-19 cases and deaths across all strategies. When community transmission was well-controlled, vaccinating the elderly first was most effective at reducing deaths. However, prioritizing working-age adults (20-59 years) was consistently best for reducing overall case numbers. These findings provide valuable insights for countries with limited vaccine access, suggesting that using any available vaccines quickly and strategically can be more beneficial than waiting for a single preferred vaccine type.
Featured Image
Photo by Adrià Crehuet Cano on Unsplash
Why is it important?
This study is crucial for addressing the global challenge of vaccine inequity during the COVID-19 pandemic, particularly for low- and middle-income countries. By using Thailand as a case study, it provides actionable insights into optimizing vaccination strategies when faced with limited vaccine supplies and varying transmission dynamics. The findings demonstrate that creative approaches, such as mixing vaccine types or prioritizing certain age groups, can significantly impact the reduction of infections and deaths. This research is especially valuable for policymakers and public health officials in resource-constrained settings, offering evidence-based strategies to maximize the impact of limited vaccine supplies.
Perspectives
Read the Original
This page is a summary of: Modeling vaccination strategies with limited early COVID-19 vaccine access in low- and middle-income countries: A case study of Thailand, Infectious Disease Modelling, November 2023, Elsevier,
DOI: 10.1016/j.idm.2023.11.003.
You can read the full text:
Contributors
The following have contributed to this page